URGN
UroGen Pharma Ltd.
NASDAQ · USHealthcareBiotechnology
$41.12+2.21%
Price as of Jul 20, 2026
URGN valuation
UroGen Pharma Ltd. valuation
Trailing, forward and enterprise-value multiples for the requested listing.
Forward multiples
- P/E forward
- 30.91x
- P/E 2026E
- —
- P/E 2027E
- 36.25x
- P/E 2028E
- 15.44x
- P/S forward
- 4.81x
Trailing multiples
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- -16.12x
- Price / sales
- 14.26x
- Price / cash flow
- -12.09x
Enterprise value
- Enterprise value
- $2.1B
- EV / sales
- 14.66x
- EV / EBITDA
- -17.78x
- EV / EBIT
- -19.03x
- Market cap
- $2.0B
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.